Skip to content
China Patent Strategy

Latest Updates on the IP Landscape in China

  • Eagle IP
  • About Our Contributors
  • Eagle IP
  • About Our Contributors
  • AI,  China,  China Patent Office,  CNIPA,  Inventions,  Inventiveness,  Patent,  Patent Re-examination and Invalidation Department,  Patent Re-examination Board,  Top 10 IP Case

    From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China

    October 21, 2025

    As AI models become versatile and adaptable across multiple contexts and industries, questions about inventive step sit at the heart of patent examination in China. The 2023 Patent Examination Guidelines (hereinafter referred to as ‘the Guidelines’) included several sessions dedicated to explaining how inventive step should be examined for AI-related inventions, featuring examples related to AI algorithms, big data, and user experience1. In the re-examination of Beijing ByteDance Network Technology Co. Ltd.’s application entitled “Method and apparatus for processing an image” (Application No. 201810734681.2)2, which was recognized as one of the Top 10 Re-examination Cases of 2025 by the CNIPA, the CNIPA focused on the following issue: when an existing…

    Read More
    eagleip No Comments

    Related Posts

    AI is magical but NOT magic! Be specific in your AI patents!

    January 9, 2025
  • China Patent Office,  CNIPA,  Inventions,  Post-Filing Data

    Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

    April 1, 2025

    “Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? This case demonstrates one example of how stark inconsistencies between post-filing (clinical trial) data and publicly available information led the CNIPA to reject a case because of false post-filing data submitted in violation of the “good faith” requirement. Case Background The disputed patent application, titled “A Type of Tini-Class Small Molecule Compound and Its Preparation…

    Read More
    eagleip No Comments

    Related Posts

    BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

    January 4, 2023

    First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing

    March 8, 2023

    Foreigners Beware: China Proposes Requiring IP Made Using Exported Chinese Genetic Resources to be Co-Owned by Chinese Collaborators

    March 22, 2023
  • China,  China Patent Office,  CNIPA,  Invalidation,  Inventions,  Patent Law

    RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

    March 10, 2025

    An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation decision in China for an RNAi patent1 was rendered in 2022 by the Patent Re-examination Board (the “Board”). We previously wrote about this case, which discussed the standards for post-filing data, sufficiency, and inventive step, particularly for RNAi inventions. Since then, two newer cases involving RNAi have also been upheld by the Board after facing similar…

    Read More
    eagleip No Comments

    Related Posts

    New Policies to Promote Importation of Innovative Drugs

    November 8, 2018

    Foreign companies transferring IP out of China: things to know

    October 25, 2018

    Is it Sufficient to Claim an Antibody only by Describing its Antigen?

    November 12, 2018
 Older Posts

Subscribe!

Don't miss a post! Subscribe here to join our mailing list. We will never share your contact information with anyone else.
Loading

Recent Posts

  • Nov 13, 2025 The Secret Prior Art Trap: A Case Study on Conflicting Applications in China
  • Oct 21, 2025 From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China
  • Sep 30, 2025 When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents
  • Sep 18, 2025 Obviousness: can features from different categories of products be combined to invalidate a design patent?
  • Sep 04, 2025 NMPA’s Releases Draft Measures for Data Protection (Data Exclusivity)

Categories

Archives

  • November 2025
  • October 2025
  • September 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • September 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • April 2023
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • April 2022
  • February 2022
  • December 2021
  • October 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • June 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018

Popular Posts

  • New Policies to Promote Importation of Innovative Drugs
  • Foreign companies transferring IP out of China: things to know
  • Is it Sufficient to Claim an Antibody only by Describing its Antigen?
  • Can Post Filing Data Overcome Inventive Step in China?
  • No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

Recent Posts

  • Nov 13, 2025 The Secret Prior Art Trap: A Case Study on Conflicting Applications in China
  • Oct 21, 2025 From Faces to Football Fields: How Applying AI Models to Different Application Fields Can Prove Inventive in China
  • Sep 30, 2025 When Standards Evolve: How China Judges Inventiveness in Next-Gen Tech Patents
  • Sep 18, 2025 Obviousness: can features from different categories of products be combined to invalidate a design patent?
  • Sep 04, 2025 NMPA’s Releases Draft Measures for Data Protection (Data Exclusivity)
  • Jun 03, 2025 How to Protect a Crystal Form (Polymorph) Patent in China
  • May 28, 2025 Why Do Examiners Fail to Recognize the Importance of my “Parameter Features”?
  • Apr 01, 2025 Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data
  • Mar 10, 2025 RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges
  • Feb 04, 2025 Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent
© 2025 Eagle IP Limited
Savona Theme by Optima Themes